Ram Jha
Overview
Explore the profile of Ram Jha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine D, Balasubramaniam N, et al.
Nat Med
. 2024 Nov;
31(1):137-143.
PMID: 39528665
Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely...
2.
Ferrari M, Righi M, Baldan V, Wawrzyniecka P, Bulek A, Kinna A, et al.
Nat Commun
. 2024 Feb;
15(1):1583.
PMID: 38383515
Peripheral T cell lymphomas are typically aggressive with a poor prognosis. Unlike other hematologic malignancies, the lack of target antigens to discriminate healthy from malignant cells limits the efficacy of...
3.
Jha R, Kinna A, Hotblack A, Bughda R, Bulek A, Gannon I, et al.
ACS Chem Biol
. 2024 Jan;
19(2):308-324.
PMID: 38243811
A versatile, safe, and effective small-molecule control system is highly desirable for clinical cell therapy applications. Therefore, we developed a two-component small-molecule control system based on the disruption of protein-protein...
4.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, et al.
Mol Ther
. 2023 Dec;
32(2):556-558.
PMID: 38103549
No abstract available.
5.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, et al.
Mol Ther
. 2023 Mar;
31(7):2089-2104.
PMID: 36945773
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. However, CD19 loss is a frequent cause of relapse. Simultaneously targeting a second antigen, CD22, may decrease...
6.
Cordoba S, Onuoha S, Thomas S, Pignataro D, Hough R, Ghorashian S, et al.
Nat Med
. 2021 Oct;
27(10):1797-1805.
PMID: 34642489
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation...